Normal full-term infants may have transient unconjugated hyperbilirubinemia that rarely exceeds 5 mg per 100 ml during the first 3 to 5 days of life (1, 2) . This so-called physiologic hyperbilirubinemia is believed to result from delayed development of the hepatic glucuronide conjugating system (3) (4) (5) , particularly glucuronyl transferase (6) . Numerous factors, such as hemolysis, infection, drugs, and prematurity influence the severity of unconjugated hyperbilirubinemia in newborn infants; however, many cases of severe neonatal unconjugated hyperbilirubinemia are observed for which no etiologic explanation is available (7, 8) . The possibility that some of these cases may have a familial basis has not been previously suggested.
Our attention was called to this possibility by observations made during the last 7 years on five mothers who had given birth to a total of 16 infants each of whom had severe transient unconjugated hyperbilirubinemia for which no adequate explanation was found. Three of these infants died of kernicterus, and one surviving child had quadriplegic cerebral palsy that probably resulted from kernicterus. Subsequent to preliminary reports of this syndrome (9, 10) , three additional families became available for study.
In 1957 Lathe and Walker demonstrated that serum from pregnant women and their newborn infants regularly inhibits the formation of conjugated bilirubin by rat liver slices in vitro (11) . In 1958 we suggested that transient familial neonatal hyperbilirubinemia may result from increased amounts of a substance in the serum of certain * Submitted for publication January 26, 1965 ; accepted May 12, 1965. This study was supported in part by research grants from the National Institutes of Health (AM-02019, pregnant women that inhibits the hepatic conjugation of bilirubin (9, 10) . Studies of serum inhibitor factor activity were, therefore, performed during subsequent pregnancies in some of these patients.
The results indicate that, beginning in the second trimester of pregnancy, mothers of infants with transient familial neonatal hyperbilirubinemia have significantly greater serum inhibitor factor activity than do normal pregnant women. This observation is probably important in the etiology and pathogenesis of transient familial neonatal hyperbilirubinemia.
Methods
Data regarding the health of the eight mothers before, during, and after each pregnancy were obtained from hospital charts and records of private physicians. A family history of severe or prolonged neonatal jaundice was specifically sought. Each of the 24 infants was born in a hospital, and data regarding birth and the neotal period were obtained from hospital records.
The following studies were performed by standard techniques to determine the cause of severe neonatal jaundice: 1) blood typing and Rh factor determination, Coombs' test, examination of peripheral blood morphology, estimation of hemoglobin concentration, and reticulocyte count; 2) serologic test for syphilis; and 3) blood cultures. Serum direct-reacting and indirect-reacting bilirubin concentrations were estimated according to Malloy and Evelyn (12) . Erythrocyte glucose-6-phosphate dehydrogenase activity was estimated in three infants, urinary sediment was examined for evidence of cytomegalic inclusion body disease in four infants, and serum glutamic-oxaloacetic and glutamic-pyruvate transaminase activities and cephalin-cholesterol flocculation were estimated in three infants.
The following specimens of serum were obtained, frozen, and stored at -40 C until assayed for inhibitor factor activity: a) Two specimens were obtained from each of 20 nonpregnant female laboratory personnel of child-bearing age.
b) Eighty-four specimens were obtained from 16 pregnant women whose previous infants had not been severely jaundiced. These sera were obtained during each trimester, at term, and during the first 2 weeks postpartum, and with the sera from nonpregnant women these specimens served as controls. Four infants weighed less than 2,500 g and were, therefore, considered premature. B) Laboratory results. The mean inhibition of direct-reacting bilirubin formation by rat liver slices by sera from control nonpregnant women, normal women during and after pregnancy, and from normal newborn infants is presented in Figures 1 and 2 . The results are similar to those published by Lathe and Walker ( 11) . Quadruplicate estimations of direct-reacting bilirubin formation by rat liver slices with and without inhibitory serum did not exceed the mean by more than 22%. Serum inhibitory activity increased during pregnancy, was less in cord blood than in maternal serum at term, and became normal in postpartum and neonatal serum by the tenth day after delivery. The mean inhibition of o-aminophenol glucuronide formation by rat liver homogenates by sera from control nonpregnant women and from normal women during and after pregnancy and from normal newborn infants is presented in Figures 3 and  4 . The results are similar to those published by Hsia and associates (13) . Duplicate estimations of o-aminophenol glucuronide formation by rat liver homogenates with and without inhibition serum were within 14%o of each other. The results follow a pattern similar to the inhibition of directreacting bilirubin formation by rat liver slices shown in Figure 1 . Figure 2 Figure 2 . The degree of inhibition is less in each subsequent time period after birth. The inhibitory activity became normal by the fourteenth day in both postpartum and neonatal serum, but remained elevated for 3 months in one mother (H.S.) and for 2 weeks in one infant (J.F. No. 2).
The effect of five inhibitory sera on direct-reacting bilirubin and o-aminophenol glucuronide formation by rat liver slices and homogenates, respectively, was not altered by 1) storage of serum at -100 C for 6 months, 2) immersion of serum in a boiling water bath for 1 hour, or 3) dialysis at 30 C for 2 days against flowing isotonic saline.
Discussion
To establish that transient familial neonatal hyperbilirubinemia is a nosologic entity, one must exclude factors known to be etiologically related to neonatal unconjugated hyperbilirubinemia.
The available data on the 24 infants do not implicate hemolysis, infection, drug effect, maternal disease, liver damage, respiratory distress syndrome, prematurity, or breast feeding as causing the hyperbilirubinemia. There is no known inherited defect in bilirubin metabolism that results in transient unconjugated hyperbilirubinemia. An inherited defect of glucuronyl transferase activity results in permanent unconjugated hyperbilirubinemia (15) (16) (17) .
Clinically transient familial neonatal hyperbilirubinemia differs from the syndrome of transient nonhemolytic unconjugated hyperbilirubinemia associated with breast feeding in some infants (18) (19) (20) . In the latter syndrome, severe and prolonged unconjugated hyperbilirubinemia is observed in breast-fed but not bottle-fed infants of mothers whose breast milk contains pregnane-3(a),20(p)-diol that competitively inhibits hepatic glucuronyl transferase activity in vitro (19) . Serum obtained from these mothers does not have significantly greater inhibitor factor than normal pregnancy serum. Kernicterus has not been observed in infants with jaundice associated with breast feeding, possibly because severe jaundice does not occur until the seventh to tenth day of life at which time the blood-brain barrier is presumably relatively impermeable to unconjugated bilirubin (8) . Only 6 of the present 24 infants were breast-fed.
Lathe and Walker described the inhibitory effect of normal pregnancy serum on direct-reacting bilirubin formation by slices of rat liver and postulated that the inhibitor was a progestational steroid (11 slices of human liver and suggested that an unidentified steroid may be the active inhibitor in man (22) . Equimolar amounts of pregnane-3 (a),-
20(a)-diol and pregnane-3(a),20(ft)-diol equally
and competitively inhibit glucuronyl transferase activity in guinea pig liver microsomes in vitro ( 19) . Administration of the latter isomer of pregnanediol to normal full-term infants resulted in nonhemolytic unconjugated hyperbilirubinemia that disappeared when steroid administration was discontinued (20) . Serum from mothers of infants with transient familial neonatal hyperbilirubinemia presumably contains the normally occurring inhibitors associated with pregnancy.
Whether the increased inhibitory effects of these sera result from qualitative or quantitative differences is unknown.
The inhibitor in the present study is nondialyzable, heat and cold stable, and temporarily associated with pregnancy. These observations suggest that it is probably a progestational steroid. Attempts to isolate the inhibitor were unsuccessful due to limited quantities of serum. Strongly inhibitory serum from three mothers of infants with transient familial neonatal hyperbilirubinemia had normal progestin activity as determined by bioassay; however, the method lacks specificity (23) . Studies of urinary pregnanediol excretion by these mothers during pregnancy have not been performed.
The inhibitor is probably of maternal origin, as maternal serum at term always produced greater inhibition than was observed with cord blood or neonatal serum, although reduced binding of the inhibitor by fetal plasma has not been excluded. The mothers of infants with transient familial neonatal hyperbilirubinemia were not icteric during pregnancy despite high titers of serum inhibitory activity. Their freedom from jaundice is probably due to their large hepatic functional reserve for transferring bilirubin from blood to bile. Although quantitation of this reserve is lacking in man, a factor of 100 has been suggested (11) , and in the rat a factor of at least 40 has been demonstrated (24, 25) .
It is postulated that the serum inhibitor factor in these mothers crosses the placenta and inhibits hepatic glucuronyl transferase in the neonate. This inhibition is superimposed on a normally occurring delayed development of the hepatic glucuronide conjugating system, particularly glucuronyl transferase activity. The placenta is believed to transfer unconjugated bilirubin from fetus to mother, whose liver conjugates and excretes bilirubin (26, 27) .
In transient familial neonatal hyperbilirubinemia, jaundice is observed within hours after birth, increases rapidly, and subsequently subsides within approximately 7 to 15 days-if the infant survives. The inhibitor is postulated to decrease hepatic glucuronide formation in the neonate, and serum inhibitory activity is either normal or declines significantly by the fourteenth day of life. By contrast, infants with prolonged unconjugated hyperbilirubinemia associated with breast feeding do not become severely icteric until approximately the fifth to tenth day of life. The inhibitory steroid that has been isolated from mothers' milk is not present in colostrum. This finding may be responsible for the delayed onset of severe neonatal jaundice in this syndrome.
The etiology of the increased serum inhibitory activity in maternal serum is unknown. An acquired abnormality seems unlikely, as drug ingestion is denied and every infant has been affected. There is no evidence for an inherited abnormality, since the mothers were unrelated and there was no family history of severe or prolonged neonatal jaundice.
Further studies are needed to establish the identity of the inhibitor, its source, and mechanism of action. Clinical recognition of the syndrome of transient familial neonatal hyperbilirubinemia should reduce the number of cases of severe neonatal unconjugated hyperbilirubinemia that are currently of unknown etiology. Furthermore, early exchange transfusion should prevent kernicterus in these infants.
Summary
A syndrome of transient familial neonatal unconjugated hyperbilirubinemia not due to known causes has been described in 24 infants of eight unrelated, healthy Caucasian mothers. Four of the infants developed kernicterus.
Beginning in the second trimester of pregnancy, sera from the eight mothers and their newborn infants inhibited direct-reacting bilirubin and o-aminophenol glucuronide formation by rat liver slices and homogenates, respectively, four to ten times more than was observed with sera from a control group of pregnant women and their infants.
The serum inhibitory factor in these women is unidentified. The fact that the inhibitor occurs in pregnancy serum suggests that it is probably a progestational steroid that inhibits glucuronyl transferase activity in the liver of neonates. The mechanism responsible for increased serum inhibitor factor activity in these women is unknown and requires further study.
Family G.O. Infant G.O. No. 1 was a full-term female infant whose birth history was benign. On the fifth day of life the infant became deeply jaundiced, and the serum bilirubin concentration was 48 mg per 100 ml. Because the infant was 5 days old and her clinical condition was good, an exchange transfusion was not performed. She is now 7 years old and is normal.
Infant G.O. No. 2, a full-term female infant, had a serum bilirubin concentration of 25 mg per 100 ml on the fourth day of life. The serum bilirubin concentration was 36 mg per 100 ml on the following day, and an exchange transfusion was performed. The child is now 5 years old and is normal.
Family V.H. Infant V.H. No. 2, a 2,977-g infant, was born of an uneventful pregnancy. He was lethargic at birth, and jaundice was noted on the fourth day of life at which time the serum bilirubin concentration was 28 mg per 100 ml and within 4 hours increased to 42 mg per 100 ml. Three exchange transfusions were performed during the subsequent 24 hours. During the last exchange transfusion, he developed a cardiac arrhythmia. Within 12 hours the serum bilirubin again rose to 41 mg per 100 ml. The infant became opisthotonic and had an abnormal Moro reflex. His clinical condition was judged to preclude a fourth exchange transfusion. The serum bilirubin reached a peak of 61 mg per 100 ml on the seventh day of life. He remained opisthotonic and decerebrate throughout his life and had frequent episodes of unexplained fever. He died at 11 months of age during such an episode. Post-mortem examination revealed extensive cerebral atrophy and a histologically normal liver. Infant W.G. No. 2, a full-term female infant, manifested intense jaundice on the second day of life. The maximal serum bilirubin concentration was 14 mg per 100 ml, which was observed on the fourth day of life. Hyperbilirubinemia slowly subsided during the subsequent 2 weeks.
Infant W.G. No. 3, a full-term male baby, developed icterus at 40 hours of life. The serum bilirubin concentration was 24 mg per 100 ml on the fifth day, and an exchange transfusion was performed. Hyperbilirubinemia disappeared by the twelfth day.
Infant W.G. No. 4 weighed 3,960 g at birth and thrived. The serum bilirubin concentration was 19 mg per 100 ml on the fourth day of life and spontaneously subsided. The child appeared clinically well throughout this period.
Family N.R. Baby N.R. No. 1, a full-term male infant, was well until the second day of life, when intense jaundice was observed. The serum bilirubin concentration rose to a maximum of 18 mg per 100 ml on the fourth day. The infant's clinical condition was good, and exchange transfusion was not performed. Hyperbilirubinemia spontaneously disappeared by the second week of life. This child is now 4 years old and is normal.
Mrs. N.R. became pregnant again in July 1960. Because of the history of unexplained jaundice in her first child, serum specimens were obtained during pregnancy, at term, and postpartum for study of inhibitor factor activity. N.R. No. 2, a full-term male infant, was born after an uneventful delivery and appeared normal. Jaundice became apparent on the second day at which time the serum bilirubin concentration was 12 mg per 100 ml, increased to 16 mg per 100 ml on the fifth day, and spontaneously subsided to normal by the fifteenth day of life. This child is now 3 years old and is normal.
Family J.F. J.F. No. 1, a full-term female infant, appeared clinically normal until the third day of life, when jaundice was observed. The serum bilirubin concentration was 16 mg per 100 ml. Laboratory studies did not reveal evidence of blood group incompatibility, sepsis, or liver damage. The child remained well, and the serum bilirubin concentration rose to 23 mg per 100 ml on the fifth day. An exchange transfusion-was performed, and hyperbilirubinemia slowly abated.
Mrs. J.F. became pregnant again in August 1961. Because of the history of unexplained jaundice in her first child, serum specimens were obtained during pregnancy, at term, and postpartum for study of inhibitor factor activity. J.F. No. 2, a full-term male infant, appeared normal at birth. Jaundice became apparent on the third day, and the serum bilirubin was 15.5 mg per 100 ml and increased to 19 mg per 100 ml on the fourth day at which time an exchange transfusion was performed. Hyperbilirubinemia subsequently subsided by the ninth day. This child is now 3 years old and appears normal.
